Corcept Therapeutics (NASDAQ:CORT) Stock: Insider Sean Maduck Sells 13,159 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Sean Maduck sold 13,159 shares of the company’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $82.25, for a total value of $1,082,327.75. Following the completion of the sale, the insider owned 9,938 shares in the company, valued at $817,400.50. The trade was a 56.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sean Maduck also recently made the following trade(s):

• On Monday, November 2nd, Sean Maduck sold 11,841 shares of Corcept Therapeutics stock. The stock was sold at an average price of $81.42, for a total transaction of $964,094.22.
• On Friday, October 2nd, Sean Maduck sold 24,587 shares of Corcept Therapeutics stock. The stock was sold at an average price of $116.28, for a total transaction of $2,858,976.36.
• On Thursday, October 1st, Sean Maduck sold 413 shares of Corcept Therapeutics stock. The stock was sold at an average price of $115.54, for a total transaction of $47,718.02.
• On Tuesday, September 1st, Sean Maduck sold 25,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $114.43, for a total transaction of $2,860,750.00.
• On Tuesday, August 25th, Sean Maduck sold 30,955 shares of Corcept Therapeutics stock. The stock was sold at an average price of $125.58, for a total transaction of $3,887,328.90.
• On Friday, August 14th, Sean Maduck sold 3,664 shares of Corcept Therapeutics stock. The stock was sold at an average price of $114.49, for a total transaction of $419,491.36.
• On Monday, August 10th, Sean Maduck sold 1,031 shares of Corcept Therapeutics stock. The shares were sold at an average price of $114.52, for a total transaction of $118,070.12.

Corcept Therapeutics Trading Down 9.6%

Shares of CORT opened at $71.63 on Friday. The stock has a market capitalization of $7.84 billion, a P/E ratio of 56.40 and a beta of 0.54. The firm’s fifty day simple moving average is $108.46 and its two-hundred day simple moving average is $75.47. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $126.38.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.17. Corcept Therapeutics had a return on equity of 22.56% and a net margin of 16.53%. The firm had revenue of $340.47 million during the quarter, compared to the consensus estimate of $339.12 million. During the same period last year, the business posted $0.16 EPS. The business’s revenue was up 64.0% compared to the same quarter last year. As a group, research analysts predict that Corcept Therapeutics Incorporated will post 1.83 EPS for the current fiscal year.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Third-quarter revenue climbed 64% year over year to about $340.5 million, while earnings of $1.01 per share beat estimates. Higher Korlym sales and growing Lifyorli uptake contributed to the results. Article: CORT’s Q3 Earnings Beat
• Positive Sentiment: Piper Sandler reaffirmed its “overweight” rating and raised its price target to $173 from $165. Article: Piper Sandler rating
• Neutral Sentiment: Corcept is awaiting a December 17 FDA decision on relacorilant and has outlined a long-term opportunity of $3 billion to $5 billion in Cushing’s revenue by 2030; both depend on regulatory and commercial success. Article: Relacorilant decision and revenue target
• Negative Sentiment: Shares have faced pressure despite the earnings beat as investors focused on company guidance. HC Wainwright also lowered its Q1 2027 EPS estimate to $0.60 from $0.74, although it kept a Buy rating and $165 price target. Article: Shares fall on guidance
• Negative Sentiment: Two insiders reported sizable sales: Roberto Vieira sold 8,333 shares, reducing his position by about 68%, while Sean Maduck sold shares in two transactions that cut his holdings by more than half. Insider sales can raise concerns, though they do not necessarily indicate a change in company prospects. Article: Corcept insider sale

Institutional Trading of Corcept Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CORT. BlackRock Inc. acquired a new stake in Corcept Therapeutics in the 2nd quarter valued at $1,080,964,000. First Trust Advisors LP increased its stake in Corcept Therapeutics by 213.5% during the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after purchasing an additional 1,480,059 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Corcept Therapeutics during the 2nd quarter valued at $49,185,000. Bank of America Corp DE bought a new stake in Corcept Therapeutics during the 2nd quarter valued at $28,569,000. Finally, Legal & General Group Plc acquired a new position in Corcept Therapeutics during the second quarter worth $18,962,000. 93.61% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CORT has been the topic of a number of research analyst reports. Piper Sandler restated an “overweight” rating and set a $173.00 price target (up from $165.00) on shares of Corcept Therapeutics in a report on Wednesday. Zacks Research lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Canaccord Genuity Group boosted their target price on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded shares of Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. Finally, Truist Financial began coverage on shares of Corcept Therapeutics in a research note on Tuesday, August 18th. They set a “buy” rating and a $164.00 target price on the stock. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Corcept Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $139.50.

About Corcept Therapeutics

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.